| 1. |
2023
Ya-Chu Tang,Yung-Jen Chuang,Hsin-Huei Chang,Shin-Hun Juang,Gow-Chin Yen,Jang-Yang Chang,Ching-Chuan Kuo.
How to deal with frenemy NRF2: Targeting NRF2 for chemoprevention and cancer therapy
. Journal of Food and Drug Analysis
.2023
;(31):387-407
|
|
| 2. |
2023
Chi-I Chang,Cheng-Chih Hsieh,Yung-Shung Wein,Ching-Chuan Kuo,Chi-Yen Chang,Jrhau Lung, Jong Yuh Cherng,Jang Yang Chang,Yueh-Hsiung Kuo.
Synthesis and Structure-Activity Relationship of Salvinal Derivatives as Potent Microtubule Inhibitors
. International Journal of Molecular Sciences
.2023
;(24)
|
|
| 3. |
2023
Sheng-Yen Hsiao, Shang-Mei Weng,Jenn-Ren Hsiao, Yi-Ying Wu,Jia-En Wu,Chia-Hao Tung,Wan-Lin Shen,Shu-Fang Sun,Wen-Tsung Huang,Cheng-Yao Lin,Shang-Hung Chen,Tse-Ming Hong,Yuh-Ling Chen,Jang-Yang Chang.
MiR-455-5p suppresses PDZK1IP1 to promote the motility of oral squamous cell carcinoma and accelerate clinical cancer invasion by regulating partial epithelial-to-mesenchymal transition.
. Journal of Experimental & Clinical Cancer Research
.2023
|
|
| 4. |
2023
Chih-Peng Lin,Shu-Hui Wu,Tzu-Yin Lin,Chia-Hui Chu,Leu-Wei Lo,Ching-Chuan Kuo,Jang-Yang Chang,Szu-Chun Hsu,Bor-Sheng Ko,Ming Yao,Jong-Kai Hsiao,Shih-Wei Wang,Dong-Ming Huang.
Lysosomal-targeted doxorubicin delivery using RBC-derived vesicles to overcome drug-resistant cancer through mitochondrial-dependent cell death
. Pharmacological Research
.2023
;(197)
|
|